Partners4Access

Weekly Roundup: July 22, 2019

Weekly Roundup: July 22, 2019

This week, the P4A team discuss the coverage of Novartis' Zolgensma in the US in particular how US health insurers have received the gene therapy. Also on the agenda was the impact of Zolgensma's launch on rival Biogen's Spinraza and the potential for dominance of the gene therapy in the spinal muscular atrophy landscape.  Presenter: Aparna Krishnan Contributor: Max Rex Producer: Aparna Krishnan

Duration: 11 min

Release Date:

Share part or all of the audio of this episode